Skip to main content
Top
Published in: Malaria Journal 1/2017

Open Access 01-12-2017 | Commentary

Ivermectin and malaria control

Authors: Satoshi Ōmura, Andy Crump

Published in: Malaria Journal | Issue 1/2017

Login to get access

Abstract

As the world begins to realize the very real prospect of eliminating malaria as a public health problem globally, the scientific community is acutely aware that novel and innovative new tools will be required if that lofty goal is to be accomplished. Moreover, the need for comprehensive, integrated products and interventions is being recognized in order for the critical ‘final steps’ toward elimination to be taken successfully. Failure to take these crucial last steps have dogged all past global disease elimination programmes, except for smallpox. The success of ivermectin in driving two of the most devastating and disfiguring neglected tropical diseases (NTD) to the brink of elimination has been well documented. The drug also bestows immeasurable non-target benefits, increasing the health and socioeconomic prospects of all communities where mass drug administration (MDA) has been carried out. Ivermectin kills a variety of parasites and insects, including the Anopheline vectors of malaria parasites. In view of long-standing MDA programmes, increasing attention is now being paid to the potential offered by re-formulating and re-purposing ivermectin to function as a feed-though mosquitocidal tool. This will provide a comprehensively beneficial weapon, for the anti-malarial armamentarium, as well as for probably improving the impact on existing target diseases. Prospects currently look highly promising, especially as the drug is already proven to be extremely safe for human use. However, for maximum impact, detailed analysis of various analogues of the unique ivermectin, as well as the parent avermectin compounds, will need to be undertaken. ‘Ivermectin’ comprises an imprecise mix of two compounds, both of which are potent anthelmintics. Yet recently, it has been confirmed that only the minor of the two component compounds is molluscicidal. Further structure activity relationship studies may well identify the analogue, analogues or combination thereof best suited for use in a concerted initiative to simultaneously tackle malaria and other NTD in poly-parasitized communities.
Literature
1.
go back to reference Chaccour C, Hammann F, Rabinovich NR. Ivermectin to reduce malaria transmission I. Pharmacokinetic and pharmacodynamic considerations regarding efficacy and safety. Malar J. 2017. doi:10.1186/s12936-017-1801-4. Chaccour C, Hammann F, Rabinovich NR. Ivermectin to reduce malaria transmission I. Pharmacokinetic and pharmacodynamic considerations regarding efficacy and safety. Malar J. 2017. doi:10.​1186/​s12936-017-1801-4.
2.
3.
4.
go back to reference Ōmura S, Crump A. The life and times of ivermectin: a success story. Nat Rev Microbiol. 2005;2:984–9. Ōmura S, Crump A. The life and times of ivermectin: a success story. Nat Rev Microbiol. 2005;2:984–9.
5.
go back to reference WHO. Update on the global status of implementation of preventive chemotherapy. (PC); 8th March 2017. Accessed 9 Mar 2017. WHO. Update on the global status of implementation of preventive chemotherapy. (PC); 8th March 2017. Accessed 9 Mar 2017.
7.
go back to reference Tesh RB, Guzman H. Mortality and infertility in adult mosquitoes after the ingestion of blood containing ivermectin. Am J Trop Med Hyg. 1990;43:229–33.PubMed Tesh RB, Guzman H. Mortality and infertility in adult mosquitoes after the ingestion of blood containing ivermectin. Am J Trop Med Hyg. 1990;43:229–33.PubMed
8.
go back to reference Chaccour C, Lines J, Whitty CJM. Effect of ivermectin on Anopheles gambiae mosquitoes fed on humans; the potential of oral insecticides in malaria control. J Infect Dis. 2010;202:113–6.CrossRefPubMed Chaccour C, Lines J, Whitty CJM. Effect of ivermectin on Anopheles gambiae mosquitoes fed on humans; the potential of oral insecticides in malaria control. J Infect Dis. 2010;202:113–6.CrossRefPubMed
9.
go back to reference Kobylinski KC, Deus KM, Butters MP, Hongyu T, Gray M, da Silva IM, et al. The effect of oral anthelmintics on the survivorship and re-feeding frequency of anthropophilic mosquito disease vectors. Acta Trop. 2010;116:119–26.CrossRefPubMedPubMedCentral Kobylinski KC, Deus KM, Butters MP, Hongyu T, Gray M, da Silva IM, et al. The effect of oral anthelmintics on the survivorship and re-feeding frequency of anthropophilic mosquito disease vectors. Acta Trop. 2010;116:119–26.CrossRefPubMedPubMedCentral
10.
go back to reference Kobylinski KC, Sylla M, Chapman PL, Sarr MD, Foy BD. Ivermectin mass drug administration for humans disrupts malaria parasite transmission in Senegalese villages. Am J Trop Med Hyg. 2011;85:3–5.CrossRefPubMedPubMedCentral Kobylinski KC, Sylla M, Chapman PL, Sarr MD, Foy BD. Ivermectin mass drug administration for humans disrupts malaria parasite transmission in Senegalese villages. Am J Trop Med Hyg. 2011;85:3–5.CrossRefPubMedPubMedCentral
12.
go back to reference Panchal M, Rawat K, Kumar G, Kibria KM, Singh S, Kalamuddin M, et al. Plasmodium falciparum signal recognition particle components and anti-parasitic effect of ivermectin in blocking nucleo-cytoplasmic shuttling of SRP. Cell Death Dis. 2014;16:e994.CrossRef Panchal M, Rawat K, Kumar G, Kibria KM, Singh S, Kalamuddin M, et al. Plasmodium falciparum signal recognition particle components and anti-parasitic effect of ivermectin in blocking nucleo-cytoplasmic shuttling of SRP. Cell Death Dis. 2014;16:e994.CrossRef
13.
go back to reference Chaccour CJ, Rabinovich NR, Slater H, Canavati SE, Bousema T, Lacerda M, et al. Establishment of the ivermectin research for malaria elimination network: updating the research agenda. Malar J. 2015;14:243.CrossRefPubMedPubMedCentral Chaccour CJ, Rabinovich NR, Slater H, Canavati SE, Bousema T, Lacerda M, et al. Establishment of the ivermectin research for malaria elimination network: updating the research agenda. Malar J. 2015;14:243.CrossRefPubMedPubMedCentral
14.
16.
go back to reference Katz N, Araújo N, Coelho PM, Morel CM, Linde-Arias AR, Yamada T, et al. Ivermectin efficacy against Biomphalaria, intermediate host snail vectors of Schistosomiasis. J Antibiot. 2017. doi:10.1038/ja.2017.31 (Epub ahead of print). Katz N, Araújo N, Coelho PM, Morel CM, Linde-Arias AR, Yamada T, et al. Ivermectin efficacy against Biomphalaria, intermediate host snail vectors of Schistosomiasis. J Antibiot. 2017. doi:10.​1038/​ja.​2017.​31 (Epub ahead of print).
17.
go back to reference Fink DW, Porras AG. Pharmacokinetics of ivermectin in animals and humans. In: Campbell WC, editor. Ivermectin and abamectin. Springer: New York; 1989. p. 113–30.CrossRef Fink DW, Porras AG. Pharmacokinetics of ivermectin in animals and humans. In: Campbell WC, editor. Ivermectin and abamectin. Springer: New York; 1989. p. 113–30.CrossRef
18.
go back to reference Baraka OZ, Mahmoud BM, Marschke CK, Geary TG, Homeida MM, Williams JF. Ivermectin distribution in the plasma and tissues of patients infected with Onchocerca volvulus. Eur J Clin Pharmacol. 1996;50:407–10.CrossRefPubMed Baraka OZ, Mahmoud BM, Marschke CK, Geary TG, Homeida MM, Williams JF. Ivermectin distribution in the plasma and tissues of patients infected with Onchocerca volvulus. Eur J Clin Pharmacol. 1996;50:407–10.CrossRefPubMed
19.
go back to reference González Canga A, Sahagún Prieto AM, Diez Liébana MJ, Fernández Martínez N, Sierra Vega M, García Vieitez JJ. The pharmacokinetics and interactions of ivermectin in humans—a mini-review. AAPS J. 2008;10:42–6.CrossRef González Canga A, Sahagún Prieto AM, Diez Liébana MJ, Fernández Martínez N, Sierra Vega M, García Vieitez JJ. The pharmacokinetics and interactions of ivermectin in humans—a mini-review. AAPS J. 2008;10:42–6.CrossRef
Metadata
Title
Ivermectin and malaria control
Authors
Satoshi Ōmura
Andy Crump
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2017
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/s12936-017-1825-9

Other articles of this Issue 1/2017

Malaria Journal 1/2017 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.